SynDermix is a private, Swiss holding company with a diversified portfolio of assets in the MedTech, Pharma, Biotech and Cosmeceutical spaces.
Our mission is to acquire or in-license the intellectual property rights to innovative life science assets, conduct limited initial development and then house them within asset-centric subsidiary companies. By doing so, we enable targeted growth, while overseeing value-driven development, and facilitate eventual transactions for the benefit of our shareholders.
BioEleSonic™, a SynDermix subsidiary, is a developer of handheld, non-invasive and connected medical devices that provide a drug-free alternative or add-on treatment option to pharmacotherapy for highly prevalent respiratory and pain disorders.
Noxogen Therapeutics, a SynDermix subsidiary, is a pharma company developing a patented, easy-to-use formulation which solves the challenges of effectively releasing nitric oxide locally, and leveraging its antimicrobial and vasodilatory properties topically.
TheraLect, a SynDermix subsidiary, is a biotechnology company developing topical applications of a recombinant plant lectin with positive Phase IIa results in epithelial healing following systemic administration.
Énielle, a SynDermix affiliate, is a Swiss skincare company and brand. Its flagship product is a skin serum, the first ever antidote to skin cell senescence, containing a signature active mixture of lectins extracted from the red kidney bean.
ATTENTION!: BEWARE OF ONGOING SCAM UNDER THE SYNDERMIX IDENTITY
If you have received any communication (email/text etc.) that SynDermix AG is hiring, these communications are in no way initiated by SynDermix AG directly or by any of its affiliates. It is a scam and please DO NOT reply.